Kobashi H, et al. - Via summarizing randomized controlled trials using a meta-analysis, researchers contrasted the clinical outcomes of accelerated corneal collagen cross-linking (ACXL) to standard corneal collagen cross-linking (SCXL) in progressive keratoconus. Six randomized controlled trials that met the eligibility criteria for this meta-analysis were identified. SCXL leads to a significantly better result in postoperative changes in best spectacle-corrected visual acuity, however, the small differences can not be clinically significant. The ACXL displays a similar effectiveness and safety profile in the 1-year follow-up, but in contrast with the Dresden protocol, it has less effect on enhancing the best spectacle-corrected visual acuity. Eventually, the disease progression is equally halted by both methods.